Navigation Links
Research Report on China's Diabetes Drug Market, 2013-2017
Date:6/12/2013

DUBLIN, June 12, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/d499df/research_report) has announced the addition of the "Research Report on China's Diabetes Drug Market, 2013-2017" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)


Diabetes refers to a series of metabolic disorder syndrome such as sugars, proteins, fat, water and electrolyte that are triggered by islet dysfunction and insulin resistance, and the latter is caused by the actions of various pathogenic factors such as genetic factors, immune disorders, microbial infections and their toxins, free radical toxins, psychological factors on body. In recent years, with the development of China's economy and improvement in people's living standards, the incidence and morbidity rates of diabetes also present the increasing trend year by year.

In China, with the aggravation of aging degree, improvement in living standards and increase in obese groups caused by unhealthy lifestyles, the prevention and treatment of diabetes are increasingly severe. Since China carried out the first survey on diabetes epidemiology in 1980, the morbidity rate of diabetes increases from less than 1% then to about 10% currently. Following tumors and cardiovascular diseases, diabetes becomes the third-largest chronic disease severely threatening people's health. In 1994, diabetics only accounted for 2.5% of the population in China. This figure increased to 5.5% in 2002 and 9.7% in 2008.

In China, the diabetes morbidity rate of people aged above 20 has reached over 9.7%, and the morbidity rate of pre-diabetes (impaired fasting glucose and impaired glucose tolerance) has reached 15.5%. In developed regions of China, diabetics in the rural population are far less than that in the urban population. However, the morbidity rate of pre-diabetes, i.e., impaired glucose regulation, in the rural population is higher than that in the urban population, whether in developed or economically-backward areas. In economically-developed regions, the diabetes morbidity rate of the urban population is 13.6%, and that of the rural population is 16.6%. In medium-developed regions, the diabetes morbidity rate of the urban population is 15.6%, and that of the rural population is 20%. This also shows that, with the development of economy and changes in lifestyles, the rural population are potential groups who are more likely to suffer from diabetes.

The market size of China's diabetes drugs is expected to maintain an annual growth rate of over 18% from 2013 to 2017.

More following information can be acquired through this report:

- Incidence of Diabetes in China
- Market Situation of China's Hospital-use Diabetes Drugs
- Competition in China's Diabetes Drug Market
- Development Trends of Diabetes Treatment Technologies and Market in China
- Following people are recommended to buy this report:
- Diabetes Drug Manufacturers
- Pharmaceutical Trade Enterprises and Hospitals
- Investors/Research Institutions Focusing on Diabetes Drugs

Key Topics Covered:

1 Overview on Diabetes Drug Market

2 Global Diabetes Drug Market

3 Overall Diabetes Drug Market in China

4 Analysis on Major Varieties in Diabetes Drug Market

5 Major Diabetes Drugs and Prices in China, 2012

6 Development Trends of Diabetes Drugs

For more information visit http://www.researchandmarkets.com/research/d499df/research_report

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Wolters Kluwer Research Now Available via Bloomberg Tradebook
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. New England Biolabs Introduces Polbase, an Information Repository of Scientific Data for Polymerase Researchers
4. Researching graphene nanoelectronics for a post-silicon world
5. In new quantum-dot LED design, researchers turn troublesome molecules to their advantage
6. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
7. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
8. Multidisciplinary team of researchers develop world’s lightest material
9. K computer research results awarded ACM Gordon Bell Prize
10. ResearchMoz: Ophthalmic Devices Market to 2017 - Glaucoma and Cataract Surgery Devices, Minimally Invasive Procedures in Ophthalmic Surgery to Drive the Ophthalmic Surgery Market
11. Researchers shrink tumors and minimize side effects using tumor-homing peptide to deliver treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Tenn. , Feb. 24, 2017 ... ("Provectus" or the "Company"), a clinical-stage oncology and ... regarding the deadline to participate in its previously ... units, consisting of shares of common stock and ... and holders of listed warrants. ...
(Date:2/24/2017)... Cord Blood Corporation (NYSE: CO ) ("CCBC" ... collection, laboratory testing, hematopoietic stem cell processing and stem ... for the third quarter and first nine months of ... Third Quarter of Fiscal 2017 Highlights ... by 18.6% to RMB200.9 million ($28.9 million). ...
(Date:2/24/2017)... DIEGO , Feb. 24, 2017  OncoSec Medical ... cancer immunotherapies, will host a Key Opinion Leader event ... as an oral and poster presentation at the upcoming ... plan. The KOL event will be held in-person and ... PM EST / 9:00 AM PST at the Lotte ...
(Date:2/23/2017)... - The Fight Against Cancer Innovation Trust (FACIT) and ... to report that Fusion Pharmaceuticals Inc. (Fusion) has closed ... Innovation – JJDC, Inc. (JJDC) as the lead investor. ... Partners, and Genesys Capital, as well as founding investor ... ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/26/2017)... CITY , Jan. 26, 2017  Crossmatch, a ... unveiled a new solution aimed at combatting fraud, waste ... solution was introduced at the Action on Disaster Relief ... key meeting point for UN agencies and foreign assistance ... Fraud, waste and abuse are a largely unacknowledged ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):